MENU
NOV 15, 2018 2:00 AM PST

Towards commercial manufacture of pluripotent stem cell derived therapies

Speaker
  • Senior Scientist, Cell and Gene Therapy Catapult
    Biography
      Rhys Macown, Ph.D, is a senior scientist in the process industrialisation team at Cell and Gene Therapy Catapult UK. Rhys earnt a BE(Hons) in chemical and process engineering at University of Canterbury (NZ) before starting his career with a PhD in biochemical engineering in Prof. Nicolas Szita's group at University College London. There he designed and tested a microfluidic system for the 2D adherent culture of pluripotent stem cells with fine control over the micro-environment. Since joining the Cell and Gene Therapy Catapult in 2014, Rhys has been continually active on fee-for-service, collaborative, and core-funded projects developing pluripotent stem cell based processes and has played a leading role exploring the 3D expansion of pluripotent stem cells as aggregates.

    Abstract

    In contrast to autologous cell therapies, allogeneic therapies do not require collection of starting material from patients and could: be manufactured in larger batches, be made available “off-the-shelf”, and potentially utilise established biopharma manufacturing technologies. Despite this, allogeneic therapies constitute half of pre-clinical trials and a third of clinical trials in the UK. In an addition to the potential for an immune response, another major barrier to the adoption of allogeneic therapies is current manufacturing cost which increases when using pluripotent stem cells (PSC) as starting material. The manufacturing process is often open and manual, utilising 2D, adherent culture systems and xeno or serum containing materials. As such, these processes are regulatorily challenging and impractical to scale-up to meet market demands. This talk will cover our work to date and future plans in addressing these barriers and realising the potential of PSC-derived allogeneic therapies.

    The Cell and Gene Therapy (CGT) Catapult have been working to address some of the challenges of manufacturing processes for PSC derived therapies, towards improving commercial viability. We used regulatorily amenable starting materials, developed invasive and non-invasive methods for process characterisation, developed exemplar processes for the expansion of pluripotent aggregates in stirred tank reactors, and developed concentration and wash processes for large-scale PSC processing. CGT Catapult’s next development focuses are the scale-up and intensification of PSC expansion in stirred tank reactors, translation of differentiation processes to automated and scalable culture systems, and cost of goods reduction.


    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    DEC 09, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 09, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 09, 2020 TIME: 09:00am PDT Hematopoietic stem cells (HSCs) ensure homeostasis of blood throughout life. In this webinar, we share insights into the smart and easy isolation, c...
    Loading Comments...
    Show Resources
    Attendees
    • See more